CMA Intermediate · Financial Management and Business Data Analytics · Capital Budgeting
A firm has two mutually exclusive projects. Project X has a higher NPV but a lower IRR than Project Y. Under the NPV approach consistent with the firm's objective of shareholder wealth maximisation, which action is appropriate?
Accept Project X. When rankings conflict for mutually exclusive projects, the higher NPV is preferred because NPV shows the absolute rupee addition to shareholder wealth, the objective of financial management, whereas IRR is only a percentage return and may favour a smaller or shorter project.
- AAccept Project Y because IRR is higher
- BAccept Project X because it adds more absolute valueCorrect
- CAccept both projects
- DReject both projects because their rankings conflict
Explanation
For mutually exclusive projects, NPV measures the absolute increase in shareholder wealth, which is the firm's objective. IRR is a percentage and can mislead when scale or timing differ. So the project with the higher NPV, X, is chosen. Accepting both is impossible because the projects are mutually exclusive.
Did you get it right without looking?
One question tells you little. A timed set on Capital Budgeting shows your real accuracy, how long you take and where you lose marks.
More Capital Budgeting questions
- Kaveri Foods plans a project with annual sales of Rs 8,00,000, cash operating costs of Rs 4,00,000 and depreciation of Rs 1,00,000 per year.…
- Ganga Foods' project A has IRR 18% and NPV ₹40,000 at the 12% cost of capital; project B is mutually exclusive, with IRR 15% and NPV ₹55,000…
- Narmada Ltd. has a 3-year project costing ₹1,00,000 now. Inflows are ₹50,000 at the end of Year 1, ₹60,000 at Year 2 and ₹70,000 at Year 3. …
- A firm sets a target ARR of 18% on initial investment. Project P costs Rs 5,00,000 and yields average annual accounting profit of Rs 80,000.…
- Sundaram Textiles must choose one of two machines at a 10% cost of capital, each of which can be replaced with an identical one at the end o…
- Kaveri Pharma's project costs ₹2,00,000 and gives inflows of ₹1,20,000 at the end of Year 1 and ₹1,44,000 at the end of Year 2. Using the IR…